Grail Q2 2024 Earnings Report $24.10 +0.48 (+2.03%) (As of 09:09 AM ET) Earnings HistoryForecast Grail EPS ResultsActual EPS-$5.30Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AGrail Revenue ResultsActual Revenue$31.97 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGrail Announcement DetailsQuarterQ2 2024Date8/13/2024TimeN/AConference Call ResourcesGRAL Earnings History URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Grail Earnings HeadlinesGrail (NASDAQ:GRAL) versus Guardant Health (NASDAQ:GH) Head to Head AnalysisDecember 17 at 3:21 AM | americanbankingnews.comGrail: Lack Of Near Term Catalyst; Market Likely To Lose Interest SoonDecember 16 at 3:18 AM | seekingalpha.com50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. December 18, 2024 | Chaikin Analytics (Ad)Canyon Grail CF SL 7 AXS review: a gravel bike of two halves?December 8, 2024 | msn.comWorld's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumblesDecember 5, 2024 | marketwatch.comGRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 3, 2024 | prnewswire.comSee More Grail Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Grail? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grail and other key companies, straight to your email. Email Address About GrailGrail (NASDAQ:GRAL), a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.View Grail ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
